Project
A Phase III, randomized, double-blinded, placebo-controlled study of Tiragolumab, an Anti-Tigit Antibody, in combination with Atezolizumab compared with placebo in combination with Atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1 selected Non-Small Cell Lung Cancer
Ongoing - recruitment closed · 2020 until 2099
Jörger Markus, Berbic Hong Phuong, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2020
End Date
2099
Financing
Industry
Labels
lung cancer